Skip to content
Screener

iRadimed IRMD Q3 2025 earnings

Reported November 3, 2025 · Before market open

Revenue$21.2MMiss by $394.9K
EPS$0.47Miss by $0.01
Revenue estimate$21.6M
EPS estimate$0.48

Next report

Nov 2, 2026 (in a month)
Revenue estimate$23.2M
EPS estimate$0.52

Financials

Q3 2025

Income statement

See full
Revenue$21.2M+15.7%
Gross profit$16.5M+16.2%
Operating income$6.8M+18.0%
Net income$5.6M+10.4%
EPS (diluted)$0.43+7.5%

Balance sheet

See full
Cash & equivalents$56.5M+9.3%
Total equity$98.4M+17.9%
Total assets$114.7M+21.7%

Cash flow

See full
Operating cash flow$7.0M-23.4%
CapEx$1.1M-70.1%
Free cash flow$5.8M+10.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$905.16M+42.1%
P/E42.7×+8.5×
P/S11.2×+2.3×

Profitability

See full
Gross margin77.1%-0.1pp
Operating margin30.9%+1.0pp
Net margin26.3%+0.2pp
FCF margin18.3%-6.6pp

Returns & leverage

See full
Return on equity23.3%-0.3pp
Current ratio6.6×-2.6×

FAQ

When did iRadimed report Q3 2025 earnings?
iRadimed (IRMD) reported Q3 2025 earnings on November 3, 2025 before market open.
What were iRadimed's Q3 2025 revenue and EPS?
iRadimed reported revenue of $21.2M and eps of $0.47 for Q3 2025.
Did iRadimed beat estimates in Q3 2025?
Revenue missed the consensus estimate of $21.6M by $394.9K. EPS missed the consensus estimate of $0.48 by $0.01.
How did iRadimed's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.7% from $18.3M a year earlier and eps grew 9.3% from $0.43.
Where can I find iRadimed's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-105298) and the 10-Q periodic report (0001104659-25-105538) directly on SEC EDGAR. The filing index links above go to sec.gov.